Nektar Therapeutics (NASDAQ:NKTR) SVP Stephen K. Doberstein sold 43,677 shares of the firm’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $24.97, for a total value of $1,090,614.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nektar Therapeutics (NKTR) traded down 2.60% during mid-day trading on Tuesday, hitting $23.27. The stock had a trading volume of 1,152,536 shares. The company’s market cap is $3.64 billion. The firm’s 50-day moving average price is $21.82 and its 200 day moving average price is $20.40. Nektar Therapeutics has a one year low of $11.41 and a one year high of $25.02.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The business had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. During the same period last year, the company earned ($0.36) EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, equities research analysts anticipate that Nektar Therapeutics will post ($0.98) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/10/stephen-k-doberstein-sells-43677-shares-of-nektar-therapeutics-nktr-stock.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Louisiana State Employees Retirement System lifted its stake in Nektar Therapeutics by 0.8% during the 2nd quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock worth $1,236,000 after acquiring an additional 500 shares in the last quarter. LS Investment Advisors LLC lifted its stake in Nektar Therapeutics by 8.8% during the 2nd quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after acquiring an additional 535 shares in the last quarter. World Asset Management Inc lifted its stake in Nektar Therapeutics by 5.6% during the 2nd quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 539 shares in the last quarter. Municipal Employees Retirement System of Michigan lifted its stake in Nektar Therapeutics by 1.7% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 34,920 shares of the biopharmaceutical company’s stock worth $820,000 after acquiring an additional 570 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Nektar Therapeutics by 14.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 692 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

NKTR has been the subject of a number of analyst reports. HC Wainwright initiated coverage on Nektar Therapeutics in a research report on Monday, August 7th. They issued a “buy” rating and a $31.00 price target for the company. BidaskClub upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. William Blair restated an “outperform” rating on shares of Nektar Therapeutics in a research report on Monday, June 26th. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a research report on Friday, August 18th. Finally, Mizuho initiated coverage on Nektar Therapeutics in a research report on Tuesday, September 26th. They issued a “buy” rating and a $30.00 price target for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $26.80.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.